Sepracor submits NDA for epilepsy candidate

The USA's Sepracor has submitted a New Drug Application to the Food and Drug Administration for the use of Stedesa (eslicarbazepine) as  adjunctive therapy in the treatment of partial-onset seizures in adults  with epilepsy.

Stedesa is a novel, voltage-gated sodium channel blocker that has been  designed to reduce the frequency of partial-onset seizures.

"If approved, Stedesa has the potential to be a meaningful new treatment  for patients with epilepsy," said Mark Corrigan, executive vice  president of R&D. "Clinical studies have indicated that Stedesa has the  potential to reduce seizure frequency, provide simpler dosage titration  and reduce side effects with once-daily dosing," he added.